This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

proofread

BTK inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification

leukemia
Credit: Unsplash/CC0 Public Domain

A new research perspective titled "Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification" has been published in Oncotarget.

In this new perspective, researchers Jai N. Patel, Jai Singh, and Nilanjan Ghosh from Atrium Health discuss Ibrutinib—the first Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of patients with (CLL).

"While producing durable responses and prolonging survival, roughly 20–25% of patients experience dose-limiting side effects, mostly consisting of cardiovascular toxicities like severe hypertension and ," the researchers write.

While clinical predictors of BTK inhibitor-related cardiotoxicity have been proposed and may aid in , there is no routine risk model used in clinical practice today to identify patients at highest risk. A recent study investigating genetic predictors of ibrutinib-related cardiotoxicity found that in KCNQ1 and GATA4 were significantly associated with cardiotoxic events. If replicated in larger studies, these biomarkers may improve risk stratification in combination with clinical factors.

"A clinicogenomic risk model may aid in identifying patients at highest risk of developing BTK inhibitor-related cardiotoxicity in which further risk mitigation strategies may be explored," the researchers add.

More information: Jai N. Patel et al, Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification, Oncotarget (2024). DOI: 10.18632/oncotarget.28589

Journal information: Oncotarget
Provided by Impact Journals LLC
Citation: BTK inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification (2024, June 4) retrieved 18 July 2024 from https://medicalxpress.com/news/2024-06-btk-inhibitor-cardiotoxicity-quest-biomarkers.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Fixed-duration ibrutinib plus venetoclax may benefit patients with high-risk chronic lymphocytic leukemia

 shares

Feedback to editors